A clinical trial testing the safety and tolerability of Brenig Therapeutics‘ BT-267, a potential disease-modifying therapy for Parkinson’s due to an unknown cause — known as idiopathic — or disease associated with LRRK2 gene mutations, has begun dosing healthy volunteers. Following this initial assessment — the first-in-human trial of…
The first six Parkinson’s disease patients given the investigational stem cell-based therapy TED-A9 in a clinical trial showed safety and an easing in their symptoms over one year of follow-up, the company developing the treatment, S.Biomedics, reported. A total of 12 adults, all diagnosed with Parkinson’s…
Researchers have developed a “double-hit” rat model of Parkinson’s disease wherein neurodegeneration is driven by both genetic susceptibility and environmental exposure to toxins. The rats were genetically engineered to accumulate human alpha-synuclein protein in the brain like existing models, but were also injected with an inflammation-inducing toxin. The animals…
HL192, an experimental oral therapy being developed to treat Parkinson’s disease, was tolerated well by healthy volunteers in a first-in-human clinical trial. The therapy’s developers — Nurron Pharmaceuticals, working in partnership with Hanall Biopharma and Daewoong Pharmaceutical — said they are planning a trial to…
People with Parkinson’s disease who have orthostatic hypotension — that’s where the blood pressure drops suddenly upon standing up from a sitting or lying position — appear more likely to develop heart and digestive problems, act out their dreams, and go through motor fluctuations, a study finds. These clinical…
Ochsner Health, a healthcare provider in the U.S. Gulf South, has been named one of six new study sites by the Global Parkinson’s Genetics Program (GP2), which is studying the genetic basis of Parkinson’s disease among underrepresented populations. Increased genetic knowledge of these populations may support the…
Angels on Call, a home care services provider, has been granted Certified Parkinson Disease Care (CPDC) accreditation by the Parkinson’s and Movement Disorders Alliance (PMD Alliance). The agency became the first in its field to earn the certification in the U.S. The accreditation involves training staff to…
While loss of dopamine is a hallmark of Parkinson’s disease, patients with tremor may actually have pools of dopamine in a specific region of the brain, a study by researchers at Champalimaud Foundation in Portugal found. The results could pave the way for targeted treatments to control shaking at…
Mice modeling Parkinson’s disease performed better on tests of memory and spatial recognition when given daily under-the-skin injections of PNA5, an experimental ProNeurogen therapy targeting cognitive symptoms — suggesting the treatment’s potential to slow cognitive decline in patients. In this preclinical study, researchers from the University of Arizona…
An upcoming Phase 2 clinical trial is due to test NEU-411, a brain-penetrant oral small molecule that Neuron23 is developing to slow the progression of Parkinson’s in people with early-stage disease who carry variations in the LRRK2 gene. The trial, called NEULARK (NCT06680830), is expected to…
Get regular updates to your inbox.
